XML 97 R33.htm IDEA: XBRL DOCUMENT v3.23.3
License revenue - Narrative (Details)
3 Months Ended 6 Months Ended 9 Months Ended
Jan. 09, 2023
USD ($)
Sep. 30, 2023
USD ($)
performanceObligation
Jun. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
performanceObligation
Sep. 30, 2022
USD ($)
Disaggregation of Revenue [Line Items]              
Distinct performance obligation | performanceObligation   1       1  
License revenue              
Disaggregation of Revenue [Line Items]              
Revenue from contract with customer   $ 406,000   $ 2,369,000   $ 1,698,000 $ 2,369,000
License revenue | Cabaletta Bio Inc. (“Cabaletta”)              
Disaggregation of Revenue [Line Items]              
Revenue from contract with customer $ 1,200,000   $ 0   $ 1,200,000    
License revenue | Investee of Syncona              
Disaggregation of Revenue [Line Items]              
Revenue from contract with customer   350,000       350,000  
Remaining performance obligation, variable consideration amount   $ 350,000       $ 350,000  
Development and Commercialization of mRNA Therapeutics | Moderna              
Disaggregation of Revenue [Line Items]              
Revenue from contract with customer       $ 2,200,000     $ 2,200,000